Prostaglandins in migraine: Update

Current Opinion in Neurology

Volumn 26, Issue 3, 2013, Pages 269-275

  Antonova, Maria ^a   Wienecke, Troels ^a   Olesen, Jes ^a   Ashina, Messoud ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

human models of migraine; migraine; prostaglandin receptor antagonist; prostaglandins

Indexed keywords

7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CYCLIC AMP; ILOPROST; LATANOPROST; MESSENGER RNA; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ALLODYNIA; DURA MATER; HEADACHE; HUMAN; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY PAIN; MAST CELL; MAST CELL DEGRANULATION; MIDDLE CEREBRAL ARTERY; MIGRAINE; MIGRAINE WITHOUT AURA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SPINAL GANGLION; STIMULATION; TRIGEMINAL NUCLEUS; UPREGULATION;

ANIMALS; CEREBRAL ARTERIES; HEADACHE; HUMANS; MIGRAINE DISORDERS; PAIN; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN;

EID: 84877707260     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328360864b     Document Type: Review

References (83)

1. von Euler US. On the specific vasodilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J Physiol 1936; 88:213-234.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-235.
3. Carlson LA, Ekelund LG, Oro L. Clinical and metabolic effects of different doses of prostaglandin E1 in man. Prostaglandin and related factors. Acta Med Scand 1968; 183:423-430.
4. Pardutz A, Schoenen J. NSAIDs in the acute treatment of migraine: a review of clinical and experimental data. Pharmaceuticals 2010; 3:1966-1987.
5. Tfelt-Hansen P. Triptans vs. other drugs for acute migraine. Are there differences in efficacy? [A comment]. Headache 2008; 48:601-605. (Pubitemid 351467624)
6. Parantainen J, Vapaatalo H, Hokkanen E. Relevance of prostaglandins in migraine. Cephalalgia 1985; 5 (Suppl 2):93-97.
7. Olesen J, Burstein R, Ashina M, Tfelt-Hansne P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009; 8: 679-690.
8. Bos CL, Richel DJ, Ritsema T, et al. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004; 36:1187-1205. (Pubitemid 38515660)
9. Busija D. Prostaglandins and other eicosanoids 2. In: Edvinsson L, Krause DN, editors. Cerebral blood flow and metabolism. Lippincott Williams & Wilkins; 2002. pp. 325-338.
10. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79:1193-1226. (Pubitemid 29473315)
11. Jadhav V, Jabre A, Lin SZ, et al. EP1-and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries. J Cereb Blood Flow Metab 2004; 24:1305-1316. (Pubitemid 40019155)
12. Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1995; 1259:109-119.
13. Davis RJ, Murdoch CE, Ali M, et al. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 2004; 141:580-585. (Pubitemid 38453250)
14. Maubach KA, Davis RJ, Clark DE, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 2009; 156:316-327.
15. Boullin DJ, Bunting S, Blaso WP, et al. Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man. Br J Clin Pharmacol 1979; 7:139-147. (Pubitemid 9108634)
16. Myren M, Olesen J, Gupta S. Pharmacological and expression profile of the prostaglandin I(2) receptor in the rat craniovascular system. Vascul Pharmacol 2011; 55:50-58.
17. Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol 2011; 69:635-645.
18. Bevan R, Dodge J, Nichols P, et al. Responsiveness of human infant cerebral arteries to sympathetic nerve stimulation and vasoactive agents. Pediatr Res 1998; 44:730-739. (Pubitemid 28519202)
19. Wallerstedt SM, Reinstrup P, Uski T, Bodelsson M. Effects of propofol on isolated human pial arteries. Acta Anaesthesiol Scand 1999; 43:1065-1068. (Pubitemid 29529823)
20. White LR, Leseth KH, Moller S, et al. Interleukin-1beta potentiates endothelin ET(B) receptor-mediated contraction in cultured segments of human temporal artery. Regul Pept 1999; 81:89-95. (Pubitemid 29248805)
21. He GW, Yang CQ. Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial artery. Br J Clin Pharmacol 1999; 48:207-215.
22. Ryszawa N, Rudzinski P, Piatek J, et al. Different reactivity of the proximal and distal segments of the radial artery to vasoconstrictors in patients undergoing coronary artery bypass grafting. Kardiol Pol 2007; 65:1313-1319. (Pubitemid 350164186)
23. Murray MA, Faraci FM, Heistad DD. Signal transduction pathways in constriction of the basilar artery in vivo. Hypertension 1992; 19:739-742.
24. Kapp JP, Robertson JT, White RP. Spasmogenic qualities of prostaglandin F2alpha in the cat. J Neurosurg 1976; 44:173-175.
25. Rosenblum WI. Constriction of pial arterioles produced by prostaglandin F2alpha. Stroke 1975; 6:293-297.
26. Wahl M, Schilling L, Whalley ET. Cerebrovascular effects of prostanoids. Insitu studies in pial arteries of the cat. Naunyn Schmiedebergs Arch Pharmacol 1989; 340:314-320. (Pubitemid 19240123)
27. Ellis EF, Wei EP, Cockrell CS, et al. The effect of PGF2 alpha on in vivo cerebral arteriolar diameter in cats and rats. Prostaglandins 1983; 26:917-923. (Pubitemid 14165831)
28. Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol 2012; 8:89-99.
29. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282:11613-11617. (Pubitemid 47100657)
30. Kassuya CA, Ferreira J, Claudino RF, Calixto JB. Intraplantar PGE2 causes nociceptive behaviour and mechanical allodynia: the role of prostanoid E receptors and protein kinases. Br J Pharmacol 2007; 150:727-737. (Pubitemid 46440219)
31. Kawabata A. Prostaglandin E2 and pain: an update. Biol Pharm Bull 2011; 34:1170-1173.
32. Turnbach ME, Spraggins DS, Randich A. Spinal administration of prostaglandin E2 or prostaglandin F2alpha primarily produces mechanical hyperalgesia that is mediated by nociceptive specific spinal dorsal horn neurons. Pain 2002; 97:33-45. (Pubitemid 34603307)
33. Uda R, Horiguchi S, Ito S, et al. Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice. Brain Res 1990; 510:26-32. (Pubitemid 20060798)
34. Donaldson LF, Humphrey PS, Oldfield S, et al. Expression and regulation of prostaglandin E receptor subtype mRNAs in rat sensory ganglia and spinal cord in response to peripheral inflammation. Prostaglandins Other Lipid Mediat 2001; 63:109-122. (Pubitemid 32332990)
35. Johansson T, Narumiya S, Zeilhofer HU. Contribution of peripheral versus central EP1 prostaglandin receptors to inflammatory pain. Neurosci Lett 2011; 495:98-101.
36. Lin CR, Amaya F, Barrett L, et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 2006; 319: 1096-1103.
37. Sugimoto Y, Shigemoto R, Namba T, et al. Distribution of the messenger RNA for the prostaglandin E receptor subtype EP3 in the mouse nervous system. Neuroscience 1994; 62:919-928. (Pubitemid 24325660)
38. Zhang J, Rivest S. Distribution, regulation and colocalization of the genes encoding the EP2-and EP4-PGE2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur J Neurosci 1999; 11:2651-2668. (Pubitemid 29364184)
39. Myren M, Olesen J, Gupta S. Prostaglandin E2 receptor expression in the rat trigeminal-vascular system and other brain structures involved in pain. Neurosci Lett 2012; 506:64-69.
40. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002; 8:390-396. (Pubitemid 34826725)
41. Villarreal CF, Funez MI, Figueiredo F, et al. Acute and persistent nociceptive paw sensitisation in mice: the involvement of distinct signalling pathways. Life Sci 2009; 85:822-829.
42. Harvey RJ, Depner UB, Wassle H, et al. GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 2004; 304:884-887. (Pubitemid 38620190)
43. Hori T, Oka T, Hosoi M, Aou S. Pain modulatory actions of cytokines and prostaglandin E2 in the brain. Ann N Y Acad Sci 1998; 840:269-281. (Pubitemid 28302054)
44. Oka T, Aou S, Hori T. Intracerebroventricular injection of prostaglandin E2 induces thermal hyperalgesia in rats: the possible involvement of EP3 receptors. Brain Res 1994; 663:287-292. (Pubitemid 24339044)
45. Tegeder I, Niederberger E, Vetter G, et al. Effects of selective COX-1 and-2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E2 release in the spinal cord. J Neurochem 2001; 79:777-786. (Pubitemid 33086515)
46. Sciberras DG, Goldenberg MM, Bolognese JA, et al. Inflammatory responses to intradermal injection of platelet activating factor, histamine and prostaglandin E2 in healthy volunteers: a double blind investigation. Br J Clin Pharmacol 1987; 24:753-761. (Pubitemid 18078378)
47. Taiwo YO, Levine JD. Prostaglandin effects after elimination of indirect hyperalgesic mechanisms in the skin of the rat. Brain Res 1989; 492: 397-399. (Pubitemid 19184577)
48. Taiwo YO, Levine JD. Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 1991; 44:131-135.
49. Zhang XC, Strassman AM, Burstein R, Levy D. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 2007; 322:806-812. (Pubitemid 47105821)
50. Moriyama T, Higashi T, Togashi K, et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005; 1:3.
51. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000; 1483:285-293. (Pubitemid 30029060)
52. Minami T, Uda R, Horiguchi S, et al. Allodynia evoked by intrathecal administration of prostaglandin F2 alpha to conscious mice. Pain 1992; 50:223-229.
53. Minami T, Nishihara I, Ito S, et al. Nitric oxide mediates allodynia induced by intrathecal administration of prostaglandin E2 or prostaglandin F2 alpha in conscious mice. Pain 1995; 61:285-290.
54. Rueff A, Dray A. Sensitization of peripheral afferent fibres in the in vitro neonatal rat spinal cord-tail by bradykinin and prostaglandins. Neuroscience 1993; 54:527-535. (Pubitemid 23153761)
55. Smith JA, Amagasu SM, Eglen RM, et al. Characterization of prostanoid receptor-evoked responses in rat sensory neurones. Br J Pharmacol 1998; 124:513-523. (Pubitemid 28254508)
56. Myren M, Baun M, Ploug KB, et al. Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine. Cephalalgia 2010; 30:1110-1122.
57. Ebersberger A, Averbeck B,Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999; 89:901-907. (Pubitemid 29071014)
58. Jenkins DW, Feniuk W, Humphrey PP. Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol 2001; 134:1296-1302. (Pubitemid 33097260)
59. Jenkins DW, Langmead CJ, Parsons AA, Strijbos PJ. Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett 2004; 366:241-244. (Pubitemid 39024273)
60. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010; 6:573-582.
61. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54-61. (Pubitemid 34626025)
62. Petersen KA, Lassen LH, Birk S, et al. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005; 77:202-213. (Pubitemid 40269135)
63. Levy D, Burstein R, Strassman AM. Mast cell involvement in the pathophysiology of migraine headache: a hypothesis. Headache 2006; 46:13-18.
64. Levy D, Burstein R, Kainz V, et al. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007; 130:166-176. (Pubitemid 46843463)
65. Lewis RA, Soter NA, Diamond PT, et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982; 129:1627-1631. (Pubitemid 12031103)
66. Roberts LJ, Lewis RA, Oates JA, Austen KF. Prostaglandin thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal mast cells. Biochim Biophys Acta 1979; 575:185-192. (Pubitemid 10196654)
67. Tetlow LC, Harper N, Dunningham T, et al. Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis 1998; 57:25-32. (Pubitemid 28175216)
68. Durham PL, Vause CV, Derosier F, et al. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache 2010; 50:844-851.
69. Tuca JO, Planas JM, Parellada PP. Increase in PGE2 and TXA2 in the saliva of common migraine patients. Action of calcium channel blockers. Headache 1989; 29:498-501. (Pubitemid 20318928)
70. Sarchielli P, Alberti A, Codini M, et al. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000; 20:907-918. (Pubitemid 32336718)
71. Uchiyama M, Sakai K. Increased main urinary metabolite of prostaglandin F2 alpha excretion in childhood migraine. Arch Dis Child 1988; 63:342.
72. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol 2001; 119:300-301.
73. Schytz HW, Schoonman GG, Ashina M. What have we learnt from triggering migraine? Curr Opin Neurol 2010; 23:259-265.
74. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 2008; 139:106-116.
75. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostaglandin E2 (PGE2) induces headache in healthy subjects. Cephalalgia 2009; 29:509-519.
76. Wienecke T, Olesen J, Ashina M. Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D (PGD). Cephalalgia 2011; 31:65-76.
77. Antonova M, Wienecke T, Olesen J, Ashina M. Pro-inflammatory and vasoconstricting prostanoid PGF2{alpha} causes no headache in man. Cephalalgia 2011; 31:1532-1541.
78. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura. Cephalalgia 2012; 32:822-833.
79. Wienecke T, Olesen J, Ashina M. Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 2010; 30:179-190.
80. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384:560-564. (Pubitemid 26415932)
81. Southall MD, Vasko MR. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 2001; 276:16083-16091.
82. Nakao K, Murase A, Ohshiro H, et al. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2007; 322:686-694. (Pubitemid 47105812)
83. Antonova M, Wienecke T, Maubach K, et al. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache. J Headache Pain 2011; 12:551-559.